Leukemia m4 is acute granulomonocytic leukemia, which has a five-year survival rate of roughly 30%. The five-year survival rate takes into account individual factors, disease progression, and comprehensive treatment. The survival rate of patients with acute leukemia M4 is closely related to the risk grouping of the leukemia they have, the patient’s own condition, and the treatment measures taken. 1. If the patient is a low-risk patient, the disease goes into remission with 4 courses of chemotherapy (with high-dose cytarabine consolidation therapy) and the survival rate is high. 2. However, if the patient belongs to the high-risk type or refractory relapsed acute leukemia, the survival rate is lower, and the patient’s life can only be prolonged by allogeneic hematopoietic stem cell transplantation. Underlying diseases such as heart disease, hypertension, chronic bronchitis, etc. shorten the survival of leukemia m4 patients when they are unable to undergo chemotherapy. After leukemia is diagnosed, standardized treatment as prescribed by the doctor, as well as maintaining a healthy lifestyle and a positive and optimistic mindset, will help improve the prognosis.